These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

848 related items for PubMed ID: 23918536

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis.
    Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Tamori A, Nakagawa M, Izumi N.
    J Med Virol; 2011 Mar; 83(3):445-52. PubMed ID: 21264865
    [Abstract] [Full Text] [Related]

  • 3. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.
    Nicot F, Alric L, Barange K, Métivier S, Dramard JM, Combis JM, Castan B, Meurisse JJ, Payen JL, Garipuy D, Desmorat H, Peron JM, Thebault S, Morin T, Renou C, Barel P, Guerin B, Imbert Y, Sire S, Sauné K, Chatelut E, Izopet J.
    J Med Virol; 2011 Mar; 83(3):437-44. PubMed ID: 21264864
    [Abstract] [Full Text] [Related]

  • 4. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.
    Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2009 Mar; 81(3):452-8. PubMed ID: 19152407
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [Abstract] [Full Text] [Related]

  • 11. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
    El-Shamy A, Shoji I, Kim SR, Ide Y, Imoto S, Deng L, Yoon S, Fujisawa T, Tani S, Yano Y, Seo Y, Azuma T, Hotta H.
    PLoS One; 2012 Nov; 7(2):e30513. PubMed ID: 22319571
    [Abstract] [Full Text] [Related]

  • 14. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
    Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H.
    Hepatology; 2010 Aug; 52(2):421-9. PubMed ID: 20648473
    [Abstract] [Full Text] [Related]

  • 15. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN.
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [Abstract] [Full Text] [Related]

  • 16. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P, Italian Co-infection Study (ICOS) Group.
    Antivir Ther; 2005 May; 10(2):309-17. PubMed ID: 15865225
    [Abstract] [Full Text] [Related]

  • 17. Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.
    Tamai H, Mori Y, Shingaki N, Kawashima A, Tsukuda H, Higashi K, Moribata K, Kawaguchi M, Ueda K, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M.
    Antivir Ther; 2014 May; 19(1):107-15. PubMed ID: 24162072
    [Abstract] [Full Text] [Related]

  • 18. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N, Giannelli G, Antonaci A, Antonaci S.
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [Abstract] [Full Text] [Related]

  • 19. Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C.
    Aizawa Y, Yohizawa K, Aida Y, Ishiguro H, Abe H, Tsubota A.
    Mol Cell Biochem; 2012 Jan; 360(1-2):9-14. PubMed ID: 21879313
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW, Chien RN, Yen CL, Chang JJ, Liu CJ, Lin CL.
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.